Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.50 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14244683 | 0.87 | KCNH2 (0.50) | PDE2AKCNH2ADRA2AADRA2BADRA2C | |
| SCHEMBL23980832 | 0.83 | KCNH2 (0.51) | PDE2AKCNH2PYGLMDM2ADRA2A | |
| SCHEMBL30217483 | 0.83 | KCNH2 (0.51) | PDE2AKCNH2PYGLMDM2ADRA2A | |
| SCHEMBL20235913 | 0.83 | KCNH2 (0.51) | PDE2AKCNH2PYGLMDM2ADRA2A | |
| SCHEMBL18482272 | 0.83 | KCNH2 (0.51) | PDE2AKCNH2PYGLMDM2ADRA2A | |
| SCHEMBL30446626 | 0.81 | KCNH2 (0.50) | PDE2AKCNH2PYGLMDM2ADRA2A | |
| SCHEMBL22206866 | 0.81 | KCNH2 (0.50) | PDE2AKCNH2PYGLMDM2ADRA2A | |
| SCHEMBL22206894 | 0.81 | KCNH2 (0.50) | PDE2AKCNH2PYGLMDM2ADRA2A | |
| SCHEMBL30445833 | 0.81 | KCNH2 (0.50) | PDE2AKCNH2PYGLMDM2ADRA2A | |
| SCHEMBL3195180 | 0.81 | KCNH2 (0.50) | PDE2AKCNH2PYGLMDM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145354-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-9145354-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-20150051199-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-19 | — | — | US | disclosed |
| US-20150051199-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-19 | — | — | US | disclosed |
| EP-2773615-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013064543-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051199-A1 | PHARMACEUTICAL COMPOUNDS | NR1H4, HAVCR2, NR1H3 | PDE2A 4545/4885KCNH2 1890/4885PYGL 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.